Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) shares traded down 3.9% during trading on Tuesday after HC Wainwright lowered their price target on the stock from $27.00 to $25.00. HC Wainwright currently has a buy rating on the stock. Century Therapeutics traded as low as $10.33 and last traded at $10.33. 1,363 shares changed hands during trading, a decline of 98% from the average session volume of 78,076 shares. The stock had previously closed at $10.75.
Several other equities analysts have also issued reports on IPSC. Piper Sandler boosted their price target on shares of Century Therapeutics from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Friday. Canaccord Genuity Group assumed coverage on shares of Century Therapeutics in a report on Monday, October 10th. They issued a “buy” rating and a $28.00 price target for the company. Guggenheim assumed coverage on shares of Century Therapeutics in a report on Monday, October 31st. They issued a “buy” rating and a $15.00 price target for the company. Finally, Canaccord Genuity Group assumed coverage on shares of Century Therapeutics in a report on Monday, October 10th. They issued a “buy” rating and a $28.00 price target for the company. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $25.33.
Hedge Funds Weigh In On Century Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its stake in Century Therapeutics by 7.9% in the 3rd quarter. BlackRock Inc. now owns 1,409,163 shares of the company’s stock worth $13,936,000 after purchasing an additional 102,978 shares during the period. Deep Track Capital LP raised its holdings in shares of Century Therapeutics by 270.6% in the 1st quarter. Deep Track Capital LP now owns 926,469 shares of the company’s stock valued at $11,664,000 after purchasing an additional 676,469 shares during the period. Vanguard Group Inc. raised its holdings in shares of Century Therapeutics by 49.6% in the 1st quarter. Vanguard Group Inc. now owns 819,762 shares of the company’s stock valued at $10,320,000 after purchasing an additional 271,760 shares during the period. Point72 Asset Management L.P. raised its holdings in shares of Century Therapeutics by 2.9% in the 2nd quarter. Point72 Asset Management L.P. now owns 481,000 shares of the company’s stock valued at $4,040,000 after purchasing an additional 13,610 shares during the period. Finally, DAFNA Capital Management LLC raised its holdings in shares of Century Therapeutics by 85.0% in the 2nd quarter. DAFNA Capital Management LLC now owns 475,367 shares of the company’s stock valued at $3,993,000 after purchasing an additional 218,475 shares during the period. 36.97% of the stock is owned by institutional investors and hedge funds.
Century Therapeutics Trading Down 4.2 %
The company has a quick ratio of 17.79, a current ratio of 17.79 and a debt-to-equity ratio of 0.03. The stock’s fifty day moving average price is $10.22 and its 200-day moving average price is $9.95.
About Century Therapeutics
Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company’s lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.